in vivo cell therapy

News

ASCO26: In vivo CAR-Ts in the spotlight

Data at ASCO on in vivo CAR-Ts from Kelonia and Legend add to the excitement about the emerging therapy class in both blood cancers and solid tumours.

News

Update: Lilly makes $7bn bid for in vivo CAR-T firm Kelonia

Eli Lilly is paying $3.25bn upfront for in vivo CAR-T therapy developer Kelonia, with another $3.75bn on offer if its candidates perform as hoped.

News

Lilly strikes again, buying CAR-T firm Orna for $2.4bn

In its second major deal in two days, Eli Lilly has reached an agreement to buy in vivo CAR-T developer Orna Therapeutics for up to $2.4bn.

News

Kelonia's in vivo CAR-T data will feature at ASH

Kelonia only started human testing of its in vivo CAR-T therapy for multiple myeloma in August, but will report impressive results at ASH next month.

News

BMS builds in 'in vivo' cell therapy with $1.5bn Orbital buy

Bristol Myers Squibb has ended the week with an agreement to buy Orbital Therapeutics, a developer of in vivo cell therapies, for $1.5bn in cash.

News

Umoja's in vivo cell therapy fast-tracked by FDA

A pioneer of in vivo cell therapy, Umoja has cleared another regulatory milestone by getting fast-track status for its lead blood cancer programme.

ASCO26: In vivo CAR-Ts in the spotlight

Update: Lilly makes $7bn bid for in vivo CAR-T firm Kelonia

Lilly strikes again, buying CAR-T firm Orna for $2.4bn

Kelonia's in vivo CAR-T data will feature at ASH

BMS builds in 'in vivo' cell therapy with $1.5bn Orbital buy

Umoja's in vivo cell therapy fast-tracked by FDA

ASCO 2026: Chinese firms take a front seat in oncology, with...

Discover a new era of healthcare panel engagement: Grounded ...

in vivo cell therapy

Editor's Picks